Moreover, a number of successful COVID-19 vaccines with a protection rate greater than 90%, such as BNT162b2, Moderna, and NVX-CoV2373 vaccines, were reported to exhibit Th1-cell-skewed responses of their S protein antigens during preclinical and clinical studies (170). This evidence concerns the gene PROS1 and COVID-19.